---
id: "entity-msk"
type: "entity"
entityType: "organization"
canonicalName: "Memorial Sloan Kettering Cancer Center"
aliases: ["MSK", "Memorial Sloan Kettering"]
source_timestamps: ["§ 3. Use strategic partnerships to unlock the value of AI in drug discovery and development.", "§ 5. Continue to drive global collaborations."]
tags: ["amc", "partnerships"]
related: ["action-establish-ai-governance", "action-cross-border-trials"]
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Memorial Sloan Kettering (MSK)

A leading U.S. AMC that has aggressively pursued strategic partnerships. It has partnered with **over 10 AI-driven drug-development companies** to deploy frontier algorithms across testing phases (illustrating Pillar 3 and [[action-establish-ai-governance]]), and it is a member of the **U.S.–Australia Alliance for Cancer Research and Treatment** to optimize **Phase 1 clinical trials** (illustrating Pillar 5 and [[action-cross-border-trials]]).

Canonical context: a major U.S. academic cancer center cited for translational research and partnerships. Co-author [[entity-selwyn-m-vickers]] is President & CEO of MSK, and co-author [[entity-anaeze-c-offodile-ii]] is affiliated with MSK.

**Enrichment context:** in this extraction MSK serves as an example of both strategic AI collaborations and global clinical-trial participation.